Innovator’s Pitch Challenge
Carocell Bio is revolutionising the treatment of inflammatory disease with its peptide-based, next-generation approach to promoting healthier healing and skin. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options for patients. This includes preventing traumatic scarring following tumour resection as part of cancer treatment, the treatment of burns, and AD (eczema). Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use, to penetrate skin wounds and prevent scarring after operations such as tumour resection in cancer patients, burns, and atopic dermatitis (eczema).